Cargando…
Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745629/ https://www.ncbi.nlm.nih.gov/pubmed/36523927 http://dx.doi.org/10.21037/hbsn-22-510 |
| _version_ | 1784849190526910464 |
|---|---|
| author | Hatanaka, Takeshi Naganuma, Atsushi Yata, Yutaka Kakizaki, Satoru |
| author_facet | Hatanaka, Takeshi Naganuma, Atsushi Yata, Yutaka Kakizaki, Satoru |
| author_sort | Hatanaka, Takeshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9745629 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97456292022-12-14 Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? Hatanaka, Takeshi Naganuma, Atsushi Yata, Yutaka Kakizaki, Satoru Hepatobiliary Surg Nutr Commentary AME Publishing Company 2022-12 /pmc/articles/PMC9745629/ /pubmed/36523927 http://dx.doi.org/10.21037/hbsn-22-510 Text en 2022 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Commentary Hatanaka, Takeshi Naganuma, Atsushi Yata, Yutaka Kakizaki, Satoru Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| title | Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| title_full | Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| title_fullStr | Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| title_full_unstemmed | Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| title_short | Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| title_sort | atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745629/ https://www.ncbi.nlm.nih.gov/pubmed/36523927 http://dx.doi.org/10.21037/hbsn-22-510 |
| work_keys_str_mv | AT hatanakatakeshi atezolizumabplusbevacizumabandtremelimumabplusdurvalumabhowshouldwechoosethesetwoimmunotherapyregimensforadvancedhepatocellularcarcinoma AT naganumaatsushi atezolizumabplusbevacizumabandtremelimumabplusdurvalumabhowshouldwechoosethesetwoimmunotherapyregimensforadvancedhepatocellularcarcinoma AT yatayutaka atezolizumabplusbevacizumabandtremelimumabplusdurvalumabhowshouldwechoosethesetwoimmunotherapyregimensforadvancedhepatocellularcarcinoma AT kakizakisatoru atezolizumabplusbevacizumabandtremelimumabplusdurvalumabhowshouldwechoosethesetwoimmunotherapyregimensforadvancedhepatocellularcarcinoma |